ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
10.15
-0.15 (-1.46%)
At close: Feb 3, 2026, 4:00 PM EST
10.08
-0.07 (-0.71%)
After-hours: Feb 3, 2026, 7:37 PM EST
ARS Pharmaceuticals Employees
As of September 30, 2025, ARS Pharmaceuticals had 167 total employees, including 162 full-time and 5 part-time employees. The number of employees increased by 16 or 10.60% compared to the same quarter last year.
Employees
167
Change
16
Growth
10.60%
Revenue / Employee
$854,922
Profits / Employee
-$479,281
Market Cap
1.00B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 167 | 16 | 10.60% | 162 | 5 |
| Jun 30, 2025 | 167 | 139 | 496.43% | 162 | 5 |
| Dec 31, 2024 | 160 | 134 | 515.38% | 155 | 5 |
| Sep 30, 2024 | 151 | 124 | 459.26% | 146 | 5 |
| Jun 30, 2024 | 28 | -6 | -17.65% | 23 | 5 |
| Mar 31, 2024 | 26 | -5 | -16.13% | 24 | 2 |
| Dec 31, 2023 | 26 | 6 | 30.00% | 24 | 2 |
| Sep 30, 2023 | 27 | 16 | 145.45% | 24 | 3 |
| Jun 30, 2023 | 34 | 23 | 209.09% | 29 | 5 |
| Mar 31, 2023 | 31 | 22 | 244.44% | 27 | 4 |
| Dec 31, 2022 | 20 | 11 | 122.22% | 17 | 3 |
| Jun 30, 2022 | 11 | - | - | 9 | 2 |
| Dec 31, 2021 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| AbCellera Biologics | 596 |
| Vir Biotechnology | 408 |
| Geron | 229 |
| CytomX Therapeutics | 121 |
| Nanobiotix | 103 |
| Theravance Biopharma | 97 |
| Ventyx Biosciences | 83 |
SPRY News
- 1 day ago - EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to - GlobeNewsWire
- 13 days ago - California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use - GlobeNewsWire
- 25 days ago - Bad News For Competitor Turns Into Big Win For ARS Pharma Stock - Benzinga
- 5 weeks ago - neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) - GlobeNewsWire
- 2 months ago - ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 3 months ago - ARS Pharmaceuticals, Inc. (SPRY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - ARS Pharmaceuticals: What We Learned From Q3 Earnings - Why I Maintain Hold Rating - Seeking Alpha
- 3 months ago - ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) - GlobeNewsWire